Plumb Pharmaceuticals

Executive Summary

Plumb Pharmaceuticals is a Madison, Wisconsin-based biotechnology company developing super extended-release drug delivery formulations using its proprietary Advanced Quantload (AQL™) platform. The AQL technology enables drug release rates measured in months from a single injection, addressing significant challenges in medication adherence. The company’s lead candidate targets opioid use disorder with a longer-acting formulation of naltrexone, aiming to improve compliance and reduce relapse rates compared to existing treatments. Founded in 2019, Plumb is privately held and operates in the drug delivery sector with a focus on chronic conditions requiring sustained therapeutic levels. The company’s approach offers a potential paradigm shift in treating opioid addiction, where weekly or monthly injections are common but still face non-adherence issues. By extending release to multiple months, Plumb could significantly improve patient outcomes and reduce healthcare costs. With early-stage development, the company is poised to enter clinical testing in the near term. Key upcoming milestones include the initiation of Phase 1 trials and presentation of preclinical data, which will be critical for validating the AQL platform and attracting partnerships. Plumb’s technology has broad applicability beyond addiction, offering a versatile platform for other therapeutic areas.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 Clinical Trial for PLUM-00180% success
• Q4 2026Presentation of Preclinical Data at Major Conference90% success
• 2027Strategic Partnership for Co-Development or Licensing40% success